Although CTLA-4 and PD-1 act at different checkpoints, their combined inhibition of allo- and tumor-reactive T-cells in transplant hosts accelerates oncogenesis and complicates oncologic management in this vulnerable population. This evidence concerns the gene PDCD1 and neoplasm.